Table 3.
Response to M+R-GemOx treatment (all patients and patient subsets)
| n (%) | All patients (N = 33) | Refractory to last regimen (n = 14) | Prior LOT |
Completed GemOx cycles |
Age, y |
Cell of origin by IHC |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 (n = 14) | 2 (n = 9) | >2 (n = 10) | 1 (n = 5) | 2 (n = 11) | >2 (n = 14) | <75 (n = 23) | ≥75 (n = 10) | Germinal center (n = 14) | Nongerminal center (n = 8) | |||
| ORR∗ | 17 (51.5) | 4 (28.6) | 8 (57.1) | 5 (55.6) | 4 (40.0) | 2 (40.0) | 4 (36.4) | 11 (78.6) | 12 (52.2) | 5 (50.0) | 6 (42.9) | 4 (50.0) |
| CR | 13 (39.4) | 2 (14.3) | 6 (42.9) | 4 (44.4) | 3 (30.0) | 2 (40.0) | 3 (27.3) | 8 (57.1) | 8 (34.8) | 5 (50.0) | 5 (35.7) | 3 (37.5) |
| PR | 4 (12.1) | 2 (14.3) | 2 (14.3) | 1 (11.1) | 1 (10.0) | 0 | 1 (9.1) | 3 (21.4) | 4 (17.4) | 0 | 1 (7.1) | 1 (12.5) |
| SD | 2 (6.1) | 1 (7.1) | 1 (7.1) | 0 | 1 (10.0) | 0 | 1 (9.1) | 1 (7.1) | 1 (4.3) | 1 (10.0) | 1 (7.1) | 1 (12.5) |
| PD | 7 (21.2) | 6 (42.9) | 1 (7.1) | 2 (22.2) | 4 (40.0) | 1 (20.0) | 4 (36.4) | 2 (14.3) | 6 (26.1) | 1 (10.0) | 3 (21.4) | 2 (25.0) |
| NA† | 7 (21.2) | 3 (21.4) | 4 (28.6) | 2 (22.2) | 1 (10.0) | 2 (40.0) | 2 (18.2) | 0 | 4 (17.4) | 3 (30.0) | 4 (28.6) | 1 (12.5) |
IHC, immunohistochemistry; LOT, line of therapy; NA, not assessed; SD, stable disease.
∗
Per Lugano criteria.
†
Patients with no postbaseline overall assessment.